Improved survival of biolistically transfected mouse islet allografts expressing CTLA4-Ig or soluble fas ligand

Transplantation

Volumn 66, Issue 2, 1998, Pages 194-199

  Gainer, Anita L ^a   Suarez Pinzon, Wilma L ^a   Min, Wei Ping ^a   Swiston, John R ^a   Hancock Friesen, Camille ^a   Korbutt, Gregory S ^a   Rajotte, Ray V ^a   Warnock, Garth L ^a   Elliott, John F ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LIGAND BINDING; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; SURVIVAL RATE; TISSUE TRANSPLANTATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; FAS LIGAND PROTEIN; GOLD; GRAFT SURVIVAL; IMMUNOCONJUGATES; ISLETS OF LANGERHANS TRANSPLANTATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED CBA; TRANSFECTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032558090     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199807270-00009     Document Type: Article

References (35)

1. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992; 257: 789.
2. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89: 11102.
3. Bolling S, Lin H, Turka L. The time course of CTLAIg effect on cardiac allograft rejection. J Surg Res 1996; 63: 320.
4. Baliga P, Chavin KD, Qin L, et al. CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity. Transplantation 1994; 58: 1082.
5. Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP. Transplantation tolerance induced by CTLA4-Ig. Transplantation 1994; 57: 1701.
6. Steurer W, Nickerson PW, Steele AW, Steiger J, Zheng XX, Strom TB. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. J Immunol 1995; 155: 1165.
7. Chahine AA, Yu M, McKernan MM, Stoeckert C, Lau HT. Immunomodulation of pancreatic islet allografts in mice with CTLA4Ig secreting muscle cells. Transplantation 1995; 59: 1313.
8. Gainer A, Korbutt G, Rajotte R, Warnock G, Elliott J. Expression of CTLA4-Ig by biolistically transfected mouse islets promotes islet allograft survival. Transplantation 1997; 63: 1017.
9. Trauth B, Klas C, Peters A, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301.
10. Anel A, Buferne M, Boyer C, Schmitt-Verhulst A, Golstein P. T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporine A. Eur J Immunol 1994; 24: 2469.
11. Vignaux F, Vivier E, Malissen B, Depraetere V, Nagata S, Golstein P. TCR/CD3 coupling to Fas-based cytotoxicity. J Exp Med 1995; 181: 781.
12. Suda T, Okazaki T, Naito Y, et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995; 154: 3806.
13. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169.
14. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449.
15. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630.
16. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189.
17. Lau HT, Yu M, Fontana A, Stoeckert CJ. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273: 109.
18. Yagita H, Seino K-i, Kayagaki N, Okumura K. CD95 ligand in graft rejection. Nature 1996; 379: 682.
19. Allison J, Georgiou HM, Strasser A, Vaux DL. Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997; 94: 3943.
20. Kang S-M, Schneider D, Lin Z, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med 1997; 3: 738.
21. Muruve D, Nicolson A, Manfro R, Strom T, Sukhatme V, Libermann T. Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts. Human Gene Ther 1997; 8: 955.
22. Gotoh M, Maki T, Kiyoizumi T, Satomi S, Monaco AP. An improved method for isolation of mouse pancreatic islets. Transplantation 1985; 40: 437.
23. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174 (Sept): 561.
24. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 1995; 14: 1129.
25. Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nature Med 1996; 2: 317.
26. Lacy P, Davie J, Finke E. Prolongation of islet allograft survival following in vitro culture (24C) and a single injection of ALS. Science 1979; 204: 312.
27. Terasaka R, Lacy P, Hauptfeld V, Bucy R, Davie J. The effect of cyclosporin-A, low-temperature culture, and anti-Ia antibodies on prevention of rejection of rat islet allografts. Diabetes 1986; 35: 83.
28. Gainer AL, Korbutt GS, Rajotte RV, Warnock GL, Elliott JF. Successful biolistic transformation of mouse pancreatic islets while preserving cellular function. Transplantation 1996; 61(11): 1567.
29. Yin D, Fathman CG. Induction of tolerance to heart allografts in high responder rats by combining anti-CD4 with CTLA4Ig. J Immunol 1995; 155: 1655.
30. Lin H, Bolling Sf, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993; 178: 1801.
31. Chervonsky AV, Wang Y, Wong FS, et al. The Role of Fas in autoimmune diabetes. Cell 1997; 89: 17.
32. Lau H, Stoeckert C. FasL: Too much of a good thing? Nature Med 1997; 3: 727.
33. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806.
34. Tanaka M, Suda T, Yatomi T, Nakamura N, Nagata S. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J Immunol 1997; 158: 2303.
35. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998; 4: 31.